Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Abl and Neoplasms:

Search results

Items: 1 to 20 of 21832

1.

Acute lymphoblastic leukemia with pancreas involvement in an adult patient mimicking pancreatic tumor: A case report.

Wang Y, Zhang X, Dong L, Tang K, Fang H, Tang Z, Zhang B.

Medicine (Baltimore). 2019 Jun;98(23):e15685. doi: 10.1097/MD.0000000000015685.

2.

[Clinical effect of CCLG-ALL2008 regimen in treatment of children and adolescents aged >10 years with acute lymphoblastic leukemia].

Lan Y, Chen XJ, Zou Y, Ruan M, Zhu XF.

Zhongguo Dang Dai Er Ke Za Zhi. 2019 May;21(5):405-410. Chinese.

PMID:
31104652
3.

[Severe hematologic toxicity and its impact on treatment response in newly diagnosed patients with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy].

Yu L, Qin YZ, Lai YY, Shi HX, Huang XJ, Jiang Q.

Zhonghua Xue Ye Xue Za Zhi. 2019 Apr 14;40(4):281-287. doi: 10.3760/cma.j.issn.0253-2727.2019.04.004. Chinese.

PMID:
31104438
4.

Radotinib inhibits mitosis entry in acute myeloid leukemia cells via suppression of Aurora kinase A expression.

Heo SK, Noh EK, Jeong YK, Ju LJ, Sung JY, Yu HM, Cheon J, Koh S, Min YJ, Choi Y, Jo JC.

Tumour Biol. 2019 May;41(5):1010428319848612. doi: 10.1177/1010428319848612.

PMID:
31074363
5.

Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity.

Calizo RC, Bhattacharya S, van Hasselt JGC, Wei C, Wong JS, Wiener RJ, Ge X, Wong NJ, Lee JJ, Cuttitta CM, Jayaraman G, Au VH, Janssen W, Liu T, Li H, Salem F, Jaimes EA, Murphy B, Campbell KN, Azeloglu EU.

Nat Commun. 2019 May 3;10(1):2061. doi: 10.1038/s41467-019-09936-x.

6.

[Clinical and genetic analyses of juvenile myelomonocytic leukemia].

Zeng MH, He XL, Yang MH, Zheng MC, Wan WQ, Zou RY, Chen KK.

Zhongguo Dang Dai Er Ke Za Zhi. 2019 Apr;21(4):365-369. Chinese.

7.

[Overexpression of miR-30a Promotes Apoptosis of Leukemia K562 Cells].

Xu M, Gao WW, Luo YJ, Wang Y, Tao K.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Apr;27(2):396-402. doi: 10.19746/j.cnki.issn.1009-2137.2019.02.014. Chinese.

PMID:
30998144
8.

[Clinical Characteristics of Patients with Ph+ Mixed Phenotype Acute Leukemia].

Jia YN, Li Y, Gong XY, Liu KQ, Ye L, Wang HJ, Li QH, Li CW, Wang Y, Wang JX, Mi YC.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Apr;27(2):354-359. doi: 10.19746/j.cnki.issn.1009-2137.2019.02.007. Chinese.

PMID:
30998137
9.

High Level of Circulating Microparticles in Patients with BCR/ABL Negative Myeloproliferative Neoplasm - a Pilot Study.

Aswad MH, Kissová J, Rihova L, Zavrelova J, Ovesná P, Penka M.

Klin Onkol. 2019 Spring;32(2):109-116. doi: 10.14735/amko2019109.

PMID:
30995850
10.

Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Crescenzo R, Mamolo C, Reisman A, Hochhaus A, Brümmendorf TH; BFORE Study Investigators.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1589-1599. doi: 10.1007/s00432-019-02894-3. Epub 2019 Apr 15.

PMID:
30989330
11.

Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia.

Wang R, Cong Y, Li C, Zhang C, Lin H.

Medicine (Baltimore). 2019 Apr;98(15):e15222. doi: 10.1097/MD.0000000000015222.

12.

[The mechanisms of taxodione-induced apoptosis in BCR-ABL-positive leukemia cells].

Uchihara Y, Tago K, Funakoshi-Tago M.

Nihon Yakurigaku Zasshi. 2019;153(4):147-154. doi: 10.1254/fpj.153.147. Japanese.

PMID:
30971653
13.

Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation.

Stetka J, Vyhlidalova P, Lanikova L, Koralkova P, Gursky J, Hlusi A, Flodr P, Hubackova S, Bartek J, Hodny Z, Divoky V.

Oncogene. 2019 Apr 9. doi: 10.1038/s41388-019-0813-7. [Epub ahead of print]

PMID:
30967632
14.

Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry).

Möbius S, Schenk T, Himsel D, Maier J, Franke GN, Saussele S, Pott C, Andrikovics H, Meggyesi N, Machova-Polakova K, Zizkova H, Jurcek T, Mesanovic S, Zadro R, Gottardi E, Haenig J, Schuld P, Cross NCP, Hochhaus A, Ernst T.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1645-1650. doi: 10.1007/s00432-019-02910-6. Epub 2019 Apr 2.

PMID:
30941573
15.

[Prognosis of clonal chromosomal abnormalities in Philadelphia negative metaphases cells in chronic myeloid leukemia with tyrosine kinase inhibitor therapy].

Zhao HF, Zhang Y, Hu JY, Li Z, Zhou J, Yu FK, Zu YL, Zhou H, Wei XD, Song YP.

Zhonghua Xue Ye Xue Za Zhi. 2019 Mar 14;40(3):209-214. doi: 10.3760/cma.j.issn.0253-2727.2019.03.009. Chinese.

PMID:
30929388
16.

Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.

Brattås MK, Reikvam H, Tvedt THA, Bruserud Ø.

Expert Opin Investig Drugs. 2019 May;28(5):411-420. doi: 10.1080/13543784.2019.1597052. Epub 2019 Apr 5. Review.

PMID:
30916583
17.

GATA-1: A potential novel biomarker for the differentiation of essential thrombocythemia and myelofibrosis.

Lally J, Boasman K, Brown L, Martinelli V, Cappuccio I, Sovani V, Marinaccio C, Crispino JD, Graham C, Rinaldi C.

J Thromb Haemost. 2019 Jun;17(6):896-900. doi: 10.1111/jth.14433. Epub 2019 Apr 25.

PMID:
30889303
18.
19.

Alterations in WNT Signaling in Leukemias.

Fetisov TI, Lesovaya EA, Yakubovskaya MG, Kirsanov KI, Belitsky GA.

Biochemistry (Mosc). 2018 Dec;83(12):1448-1458. doi: 10.1134/S0006297918120039. Review.

PMID:
30878020
20.

Neferine in the Lotus Plumule Potentiates the Antitumor Effect of Imatinib in Primary Chronic Myeloid Leukemia Cells In Vitro.

Zhang Y, Xiao Y, Dong Q, Ouyang W, Qin Q.

J Food Sci. 2019 Apr;84(4):904-910. doi: 10.1111/1750-3841.14484. Epub 2019 Mar 13.

PMID:
30866043

Supplemental Content

Loading ...
Support Center